FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($2.02), $0.16 worse than the analyst estimate of ($1.86). Revenue for the quarter came in at $44.7 million versus the consensus estimate of $69.2 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
... More
